Chemomab Therapeutics Management
Management criteria checks 3/4
Chemomab Therapeutics' CEO is Adi George, appointed in Jan 2011, has a tenure of 13.83 years. total yearly compensation is $330.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 3.01% of the company’s shares, worth $937.57K. The average tenure of the management team and the board of directors is 1.7 years and 3.7 years respectively.
Key information
Adi George
Chief executive officer
US$330.0k
Total compensation
CEO salary percentage | 100.0% |
CEO tenure | 13.8yrs |
CEO ownership | 3.0% |
Management average tenure | 1.7yrs |
Board average tenure | 3.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$14m |
Jun 30 2024 | n/a | n/a | -US$15m |
Mar 31 2024 | n/a | n/a | -US$19m |
Dec 31 2023 | US$330k | US$330k | -US$24m |
Sep 30 2023 | n/a | n/a | -US$29m |
Jun 30 2023 | n/a | n/a | -US$33m |
Mar 31 2023 | n/a | n/a | -US$31m |
Dec 31 2022 | US$435k | US$298k | -US$28m |
Sep 30 2022 | n/a | n/a | -US$24m |
Jun 30 2022 | n/a | n/a | -US$19m |
Mar 31 2022 | n/a | n/a | -US$16m |
Dec 31 2021 | US$488k | US$249k | -US$12m |
Sep 30 2021 | n/a | n/a | -US$9m |
Jun 30 2021 | n/a | n/a | -US$8m |
Mar 31 2021 | n/a | n/a | -US$6m |
Dec 31 2020 | US$325k | US$229k | -US$6m |
Compensation vs Market: Adi's total compensation ($USD330.00K) is below average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Adi's compensation has been consistent with company performance over the past year.
CEO
Adi George (42 yo)
13.8yrs
Tenure
US$330,000
Compensation
Dr. Adi Mor George, Ph.D. serves as Chief Executive Officer of Chemomab Therapeutics Ltd. since June 01, 2023. She is the Co-Founder of Chemomab Therapeutics Ltd.and has been its Chief Scientific Officer...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 13.8yrs | US$330.00k | 3.01% $ 937.6k | |
Chief Financial Officer | 1.4yrs | US$322.00k | 0.024% $ 7.5k | |
Chief Medical Officer & VP of Drug Development | 2yrs | US$850.00k | 0% $ 0 | |
Consulting Vice President of Investor & Public Relations | no data | no data | no data | |
Senior VP of Global Clinical Development Operations | less than a year | no data | no data |
1.7yrs
Average Tenure
53yo
Average Age
Experienced Management: CMMB's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 3.7yrs | US$330.00k | 3.01% $ 937.6k | |
Independent Director | 4.6yrs | US$123.00k | 0.75% $ 233.0k | |
Independent Chairman | 3.7yrs | US$123.00k | 0.0064% $ 2.0k | |
Independent Director | 3.7yrs | US$119.00k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.7yrs | US$123.00k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 2.4yrs | US$38.00k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
3.7yrs
Average Tenure
59.5yo
Average Age
Experienced Board: CMMB's board of directors are considered experienced (3.7 years average tenure).